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AbsTrACT
Introduction Proteinuria increases at altitude and with 
exercise, potentially as a result of hypoxia. Using urinary 
alpha-1 acid glycoprotein (α1- AGP) levels as a sensitive 
marker of proteinuria, we examined the impact of relative 
hypoxia due to high altitude and blood pressure- lowering 
medication on post- exercise proteinuria.
Methods Twenty individuals were pair- matched for sex, 
age and ACE genotype. They completed maximal exercise 
tests once at sea level and twice at altitude (5035 m). 
Losartan (100 mg/day; angiotensin- receptor blocker) and 
placebo were randomly assigned within each pair 21 
days before ascent. The first altitude exercise test was 
completed within 24–48 hours of arrival (each pair within 
~1 hour). Acetazolamide (125 mg two times per day) was 
administrated immediately after this test for 48 hours until 
the second altitude exercise test.
results With placebo, post- exercise α1- AGP levels 
were similar at sea level and altitude. Odds ratio (OR) for 
increased resting α1- AGP at altitude versus sea level was 
greater without losartan (2.16 times greater). At altitude, 
OR for reduced post- exercise α1- AGP (58% lower) was 
higher with losartan than placebo (2.25 times greater, 
p=0.059) despite similar pulse oximetry (SpO
2
) (p=0.95) 
between groups. Acetazolamide reduced post- exercise 
proteinuria by approximately threefold (9.3±9.7 vs 3.6±6.0 
μg/min; p=0.025) although changes were not correlated 
(r=−0.10) with significant improvements in SpO
2
 
(69.1%±4.5% vs 75.8%±3.8%; p=0.001).
Discussion Profound systemic hypoxia imposed by 
altitude does not result in greater post- exercise proteinuria 
than sea level. Losartan and acetazolamide may attenuate 
post- exercise proteinuria, however further research is 
warranted.
InTroDuCTIon
Proteinuria typically results from protein 
leakage from the capillary lumen through the 
glomerular filter,1 with some removal in the 
tubules, as shown by studies inhibiting renal 
tubular reabsorption with lysine infusions.2 
Comparisons between albumin, a selectively 
reabsorbed,3 66 kDa, negatively charged (pI 
4.7) protein that passes through the glomer-
ular membrane via the slit diaphragm pores,4 
and alpha-1 acid glycoprotein (α1- AGP),5–7 
a smaller (41–43 kDa) and more negatively 
charged protein (pI 2.7)5 7 indicate that 
urinary α1- AGP is a more sensitive marker of 
glomerular leakage than albumin.7–9 Urinary 
α1- AGP excretion has implicated the glomer-
ular origin of the proteinuria exhibited with 
both, altitude7 and post- exercise.5 Hypoth-
esised mechanisms for such glomerular 
leak have included changes in renal blood 
flow,5 10 increases in peritubular pressure 
and blood pressure2 (BP), hypoxia11 and 
acid–base disturbances,2 although the mech-
anisms remain unclear.12 The contributions 
of BP and hypoxia, especially to post- exercise 
proteinuria may be uniquely evaluated with 
altitude exercise.
At altitude, exercise BP is amplified13 14 and 
such exaggerations are responsive to anti-
hypertensive therapies such as angiotensin 
II type 1 (AT1) receptor antagonists or 
blockers (ARBs).13 15 ARBs reduce BP via 
several mechanisms, including selectively 
blocking angiotensin II (A- II) from binding 
to AT1s within the vasculature,16 promoting 
vasodilation. Specific to the kidney, ARBs 
summary box
 ► Post- exercise proteinuria is not directly related 
to systemic hypoxia but it is related to exercise 
intensity.
 ► Losartan may attenuate post- exercise proteinuria 
by maintaining the charge- selectivity function in the 
glomerular filter, although further investigations are 
warranted.
 ► Future proteinuria research should aim to include 
urinary alpha-1 acid glycoprotein and it should 
consider analyses using automated turbidimetric 
immunoassays.
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(eg, losartan) ‘block’ vasoconstriction imposed by A- II 
on afferent arterioles.17 ARBs also limit both, vaso-
pressin secretion and aldosterone production, further 
adding to its BP lowering effect.16 Considering these 
factors, it would be reasonable to expect altitude post- 
exercise proteinuria to be greater than at sea level and 
that AT1 blockers such as losartan could attenuate the 
post- exercise response. To evaluate this, we planned to 
compare post- exercise α1- AGP excretion between (1) sea 
level and altitude exercise and (2) losartan and placebo 
groups following exercise at altitude.
Exercise oxygen saturation is also altered at altitude and 
it is profoundly lower compared with sea level18 but it can 
be improved by acetazolamide,19 a carbonic anhydrase 
inhibitor commonly used to prevent altitude illness.20 21 
By inhibiting carbonic anhydrase, a catalyst of the revers-
ible CO
2
 hydration reaction, acetazolamide promotes 
carbonic acid formation and dissociation of H+ and 
bicarbonate in the blood21 which limits hypoxia- induced 
alkalosis and improves oxygen saturation.21 Assuming 
hypoxia as the main mechanism of post- exercise protein-
uria, altitude exercise would be expected to produce 
larger increases in post- exercise proteinuria compared 
with sea level. In addition, subsequent improvements 
in arterial oxygenation would be expected to have the 
‘reverse’ effect. To evaluate this, we planned to compare 
post- exercise α1- AGP between (1) sea level and altitude 
and (2) placebo and placebo +acetazolamide groups at 
altitude.
We hypothesised that exercise at altitude would 
increase post- exercise α1- AGP levels compared with sea 
level, primarily due to greater systemic hypoxia, and that 
losartan and acetazolamide would attenuate the observed 
increases by improving blood and peritubular pressures16 
and alleviating renal hypoxia,22 respectively.
As part of an expedition to Quito, Ecuador, we 
measured post- exercise urinary α1- AGP excretion in 
20 pair- matched individuals once at sea level (before 
placebo or losartan administration) and twice at altitude 
as outlined in the following sections.
METHODS
Design and participants
Twenty participants (14 men, 6 women) free of any pre- 
existing conditions were included in the study. ACE 
genotyping (II, ID or DD) was performed to limit poten-
tial differences between groups that could be attributed 
to ACE genotype (eg, response to losartan,23 response to 
altitude,24 etc.). Participants were pair- matched partic-
ipants for ACE genotype, age, sex, previous altitude 
exposure and glomerular filtration rate (GFR, obtained 
4 weeks prior to ascent) (figure 1).
Following matching, a double- blind, randomised, 
placebo- controlled trial design was adopted. Individ-
uals within each pair were randomly assigned to either 
placebo or losartan group (figure 1). Losartan admin-
istration (100 mg/day or placebo) began in the UK 21 
days prior to departure for Quito, Ecuador (2850 m). On 
arrival at Quito, participants ascended over 10 days to 
the Whymper Hut on the flank of Chimborazo volcano 
(5035 m, figure 1).
baseline and daily measures
Baseline measures of height, body mass, GFR and creat-
inine (μmol/L) were recorded 4 weeks prior to ascent 
(figure 1A). Estimated GFR (eGFR) was calculated for 
each individual using the Modification of Diet in Renal 
Disease study equation25:
 
eGFR(mL/min/1.73m2) = 32 788× (serum creatinine µmol/litre)−1.154
×(Age)−0.203(then 0.742 for females)  
During ascent (figure 1B), resting measures of systolic 
BP (SBP) and diastolic BP (DBP) were collected each 
morning using a manual sphygmomanometer.
Exercise protocols and measures
Sea-level exercise
Baseline sea- level graded maximal exercise tests were 
performed 4 weeks prior to ascent on a cycle ergometer 
(Alticycle) designed for altitude studies26 (figure 1A). 
Volitional fatigue was used as the primary end point crite-
rion for the test.27 Maximal power output (Watt
max
) was 
measured by the Alticycle and heart rate (HR) record-
ings were facilitated by telemetry (Polar Electro, UK).
Altitude exercise
The first altitude exercise tests were commenced on 
arrival to the Whymper Hut for five pairs (day 7) and 
completed on the following day (day 8) for remaining 
pairs (figure 1). These initial tests were immediately 
followed by acetazolamide administration (125 mg orally, 
two times per day) which occurred 48 hours prior to the 
second round of altitude exercise tests in all participants. 
Similar to the first tests, the second round of altitude 
exercise tests were performed across 2 days (on days 9 
and 10, figure 1).
At altitude, pre- exercise measurements of oxygen 
uptake (VO
2
), carbon dioxide production (VCO
2
), 
ventilation (V
E
), HR, SBP and DBP were collected. Partic-
ipants undertook a 5 min self- paced warm- up followed by 
a modified graded exercise test on the Alticycle which 
was commenced at 30% of sea- level Watt
max
. Intensity 
was increased every 3 min by 10% until the participant 
reached 80% of sea- level Watt
max
. From this point, inten-
sity was increased by 10% each minute until volitional 
fatigue. Expired respiratory gases were analysed breath- 
by- breath using a Cosmed K4b2 (Metabolic Company, 
Rome, Italy) portable metabolic system alongside contin-
uous measurements of HR (via three- lead ECG), pulse 
oximetry (SpO
2
, Datex Ohmeda 3900, GE Healthcare, 
USA) and beat- to- beat measurements of SBP and DBP 
by photoplethysmography (Portapres, Finapres Medical 
Systems BV, The Netherlands). Change in SBP and DBP 
was calculated as the difference between pre- exercise 
and the value obtained at Watt
max
. Urine specimens 
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Figure 1 (A) Visual representation of the study design. Step 1: Participants were matched for: ACE genotype (II, ID or DD; 
see table 3), age, sex previous altitude exposure, and GFR. Step 2: Within each pair, participants were randomly assigned to 
placebo or losartan groups. Step 3: Baseline characteristics were recorded and baseline exercise tests were conducted (4 
weeks before ascent) and were followed by the initiation of losartan administration (21 days before ascent). Step 4: Ascent is 
initiated with both groups ascending together in accordance with (B). Step 5: The first round of altitude exercise tests were 
conducted for members of both groups (5035 m). Step 6: Immediately following the first altitude exercise tests, acetazolamide 
was administered (125 mg orally, two times per day) and continued for 48 hours until next exercise test. Step 7: Repeat 
altitude exercise tests were conducted for all individuals (only placebo group data reported). (B) Expedition ascent profile. 
Day 0: Birmingham, UK (130 m), day 1: Quito, Ecuador (2800 m), day 2: Quito, Ecuador (2800 m), day 3: bus to Chunquiragua 
in Chaupi (3400 m), day 4: bus to Estrella del Chimborazo MARCO cruz (3950 m), day 5: Estrella del Chimborazo MARCO 
cruz (3950 m) with day hike to 5000 m and back, day 6: bus to Carrel hut (4800 m), days 7–10: Whymper hut (5035 m). GFR, 
glomerular filtration rate.
were collected surrounding exercise as outlined in the 
following section.
urine collection and storage
Twenty- four- hour urine samples were collected over 1 day 
at sea level and on each day of the expedition (10 days) 
with four aliquots (2 mL each) taken from each daily 
collection and frozen on dry ice.
For pre- exercise collections, participants were 
instructed to drink 500 mL of water between 90 and 
30 min pre- exercise and to provide a timed (60 min) urine 
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specimen immediately prior to exercise. Post- exercise 
urine specimens were collected at 60, 120 and 180 min. 
Four aliquots (2 mL each) were taken from exercise spec-
imens and frozen on dry ice, with the residual volumes 
returned to each individual’s 24 hours collection bottle. 
Urine samples were transported back to Birmingham, 
UK and stored at (–80°C) until analysis.
urine analysis
All samples were thawed at room temperature for 1 hour 
before analysis. The 24- hour urine samples were first 
analysed for α1- AGP using radial immunodiffusion (RID; 
Talks et al., 2018)7 and the results were converted to 
excretion rates (mg/24 hours or μg/min). A subset of 
samples (119 out of 201) were then analysed using a latex- 
enhanced immunoassay on the Optilite turbidimetric 
analyser (The Binding Site, Birmingham, UK; online 
supplementary appendix 1). This automated method was 
used for all exercise samples, with the analysed concen-
trations (mg/L) converted to excretion rates (μg/min) 
based on sample volumes and collection durations.
728 29
Data analysis
Statistical analyses were performed using SPSS (IBM 
SPSS Statistics, V.25). Normality of distribution was 
determined by the Shapiro–Wilk test, with data (24- 
hour urinary α1- AGP excretion) log- transformed where 
possible. Continuous variables are presented as mean±SD 
or median ±IQR where appropriate. All tests for signif-
icance were two- tailed with statistical significance set at 
p≤0.05 unless otherwise indicated.
We used independent t- tests to compare group means 
(placebo vs losartan) where data were normally distrib-
uted and when measures were not repeated (eg, age 
and baseline HR). We used repeated- measures ANOVA 
with pairwise comparisons (Bonferroni corrected) to 
determine group (placebo vs losartan) and interaction 
effects (where appropriate) across days for normally 
distributed data (eg, transformed 24- hour α1- AGP, DBP 
and SBP). We used Friedman tests to determine the 
main effect of time on α1- AGP excretion surrounding 
exercise (ie, pre-60, post-60, post-120 and post-180 min) 
where data were not normally distributed. These results 
are presented as ‘χ2(df), p value’. When appropriate, 
the post- hoc Wilcoxon signed rank test with Bonferroni 
correction for repeated measures was used to distinguish 
significance between time points (significance set at 
p≤0.0125; ie, corrected for three comparisons). We then 
used Mann–Whitney U tests to compare significant time 
points between groups (ie, placebo vs losartan at post-60 
min).
To avoid any superimposed effects of the two drugs on 
results, we limited comparisons between the two altitude 
tests (before and after acetazolamide administration, 
placebo vs placebo +acetazolamide) to individuals from 
the placebo group completing both tests (n=9, tables 1 
and 2). For these comparisons, we applied the Friedman 
test and Wilcoxon signed rank test as previously described 
with additional use of the Wilcoxon signed rank test to 
compare α1- AGP excretion rates (within- individuals) 
between placebo and placebo +acetazolamide at post-60 
min. We used Spearman’s correlation to evaluate rela-
tionships between daily measures (eg, DBP and 24 hours 
α1- AGP excretion) and exercise measures (eg, SpO
2
 and 
post- exercise α1- AGP excretion).
We calculated ORs for urinary α1- AGP excretion in 
placebo and losartan groups at rest (pre- exercise and 
post- exercise at 120 and 180 min) and with exercise (at 
post-60 min) based on the relative changes (relative 
increase (+) or decrease (−)) from baseline sea- level 
measures within each individual.
Patient and public involvement
This study was supported by the Birmingham Medical 
Research Expeditionary Society which provided input for 
the conduct of the research. Patients were not included. 
Public involvement was limited to recruitment. Notifica-
tion was given to participants at the time of consent that 
acquisition of personal data was permitted on request. 
Permission was also obtained at this time for the dissemi-
nation of de- identified data within the research team and 
only externally when a reasonable request was submitted 
directly to the corresponding author(s) of the present 
study within 6 months of its publication. A portion of the 
cohort was invited to review the research methods for 
accuracy and readability.
Ethics approval
This study did not aim to investigate any safeties or effi-
cacies of the already Food and Drug Administration 
(FDA)- approved drugs included, thus no clinical trial 
approval was obtained. There were no active FDA recalls 
for either drug for the duration of the study.
rEsulTs
baseline measures
Baseline data are presented in table 3. Placebo and 
losartan groups were not significantly different at base-
line for measures of age, body mass, height, GFR, eGFR 
or creatinine. ACE genotype was exactly matched in 9 
out of 10 pairs, with all allelic variations represented (ID, 
n=13; II, n=4 and DD, n=3; table 3).
Daily measures
Results for daily measures are presented in figure 2. 
Collectively with ascent, daily DBPs increased signifi-
cantly (p=0.04) while SBP increased, although not 
significantly (p=0.17). Daily SBPs and DBPs remained 
similar between groups with ascent (SBP, p=0.71; DBP, 
p=0.72; figure 2A,B).
Exercise studies
Baseline sea-level exercise
Baseline exercise data are presented in table 1. All 20 
participants achieved exhaustion during baseline sea- 
level exercise tests. Baseline measures of HR
max
, absolute 
School. Protected by copyright.
 o
n
 April 20, 2020 at Barnes Library M
edical
http://bmjopensem.bmj.com/
BM
J O
pen Sport Exerc M
ed: first published as 10.1136/bmjsem-2019-000662 on 26 March 2020. Downloaded from 
5Joyce KE, et al. BMJ Open Sp Ex Med 2020;6:e000662. doi:10.1136/bmjsem-2019-000662
Open access
Table 1 Maximal exercise test results compared between groups at baseline and twice at altitude
Placebo Losartan P value
Sea- level exercise
  HR
max
 (bpm) 171.7±16.5 173.7±22.9 0.82
  Absolute Watt
max
 (W) 243±66 238±70 0.89
  Relative Watt
max
 (W) 3.3±0.5 3.1±0.5 0.41
Placebo Losartan P value
Placebo 
+acetazolamide
P 
value
Altitude exercise
Pre- exercise
   HR (bpm) 80±12 76±15 0.50 78±14 0.10
   SBP (mm Hg) 162±28 159±22 0.82 149±22 0.17
   DBP (mm Hg) 79±6 76±12 0.22 76±8 0.61
   SpO
2
 (%) 76±7 78±5 0.40 84±4 <0.01*
Maximal exercise
   HR
max
 (bpm) 152±24 143±35 0.78 147±21 0.63
   SBP at Watt
max
 (mm Hg) 229±47 221±50 0.81 232±47 0.43
   ΔSBP (mm Hg) 70±31 66±42 0.80 82±46 0.26
   DBP at Watt
max
 (mm Hg) 87±13 85±19 0.81 96±15 0.08
   ΔDBP (mm Hg) 8±10 9±11 0.93 19±14 0.04 *
   SpO
2
 at Watt
max
 (%) 70±5 71±7 0.89 77±4 <0.01*
   Watt
max
 (W) 155±52 138±55 0.53 149±46 0.71
   Watt
max
(W/kg) 2.1±0.6 1.8±0.5 0.23 2.0±0.5 0.18
Values are presented as mean±SD. Change (Δ) SBP and ΔDBP represent the differences between pre- exercise and Watt
max
 measurements.
*Represents a significant (p≤0.05) difference between placebo and placebo +acetazolamide altitude exercise tests (n=9; within- individual 
comparisons).
DBP, diastolic blood pressure; HR, heart rate (bpm); HR
max
, maximal heart rate; SBP, systolic blood pressure (mm Hg); SpO
2
, oxygen 
saturation pulse oximetry (%); Watt
max
, wattage at volitional fatigue (presented in absolute, W, and relative, W/kg, units.
Watt
max
 and relative Watt
max
 were not different between 
groups (table 1).
Altitude exercise (losartan vs placebo)
Altitude exercise data are presented in table 1. Pre- 
exercise measures of SpO
2
, HR, SBP and DBP were 
not different between groups. All participants achieved 
exhaustion during the first altitude exercise tests. At alti-
tude, both absolute Watt
max
 and relative Watt
max
 were 
reduced by ~40% compared with sea level but remained 
similar between groups. HR
max
, SpO
2
 at Watt
max
, SBP at 
Watt
max
 and DBP at Watt
max
 were also similar between 
groups. Changes in SBP and changes in DBP did not 
differ between groups.
Altitude exercise (placebo vs placebo +acetazolamide)
Nine individuals from the placebo group went on to 
complete the second altitude exercise test following acet-
azolamide administration. These data are presented in 
table 1. Pre- exercise HR, SBP and DBP were no different 
between placebo and placebo + acetazolamide, although 
pre- exercise SpO
2
 was significantly improved with acet-
azolamide (p<0.01).
Altitude exercise measures of absolute Watt
max
, rela-
tive Watt
max
, SBP at Watt
max
, DBP at Watt
max
 and HR
max
 
were similar before and after acetazolamide, as were 
the changes in SBP. In contrast, changes in DBP were 
significantly greater with acetazolamide (p=0.04). SpO
2
 
at Watt
max
 was significantly increased with acetazolamide 
(p<0.01).
urine studies
Twenty-four-hour excretion
Twenty- four- hour urinary α1- AGP excretion (μg/min) 
significantly increased with ascent (p<0.01) although 
no differences were observed between groups for 
log- transformed excretion rates (p=0.97, figure 2). 
Twenty- four- hour urinary α1- AGP excretion correlated 
with DBP but not with SBP on days 1 (r=0.63, p=0.05), 6 
(r=0.75, p=0.01) and 9 (r=0.90, p=0.04) of the expedition 
in the losartan group only.
Baseline sea level
Baseline urine results are presented in table 2 and 
figure 3A. Urinary α1- AGP excretion rates were no 
different between groups before exercise. Exercise 
increased urinary α1- AGP excretion in both placebo 
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Table 2 Comparisons of pre- exercise and post- exercise α1- AGP excretion between groups at sea level and twice at altitude
Placebo P value (Z- score) Losartan P value (Z- score)
Baseline α1- AGP excretion
  Pre- exercise 3.5±4.4 0.038 (−2.07) 1.4±2.8 0.028 (−2.20)
  ΔPre-0 min to 
post-60 min
8.4±16.3 – 13.8±22.5 –
  Post-60 min 13.7±13.8 – 13.5±33.3 –
  Post-120 min 1.8±1.2 0.008 (−2.67)* 1.6±2.7 0.013 (−2.50)*
  Post-180 min 1.5±2.2 0.008 (−2.67)* 1.2±1.7 0.017 (−2.38)
  Placebo P value (Z- score) Losartan P value (Z- score)
Placebo 
+acetazolamide
P value (Z- 
score)
Altitude α1- AGP excretion
  Pre- exercise 3.1±5.3 0.022 (−2.29) 2.4±3.4 0.009 (−2.60)* 4.4±5.7 0.16 (−1.4)
  ΔPre- to post-60 
min
7.9±14.3 – 4.8±9.9 – 1.2±11.03† 0.16 (−1.4)
  Post-60 min 11.5±19.2 – 8.2±5.9 – 7.7±12.1 –
  Post-120 min 3.2±2.4 0.007 (−2.70)* 2.8±4.4 0.012 (−2.52)* 3.4±5.0 –
  Post-180 min 1.3±4.3 0.011 (−2.55)* 1.5±1.5 0.018 (−2.4) 2.7±4.2 0.025 (−2.24)
Urinary α1- AGP excretion rates (μg/min) are presented as median ±IQR before (pre- exercise, 0 min) and after (post-60, post-120 and 
post180 min) exercise initiation. Results are presented for placebo versus losartan (baseline), placebo versus losartan (first altitude 
exercise) and pre- acetazolamide versus acetazolamide (first compared with second altitude exercise).
*Represents the significance of post-60 min α1- AGP excretion (p≤ 0.0125) compared with excretion at other time points.
†Represents the significant (p≤0.05) difference between groups (ie, placebo vs losartan or placebo vs placebo +acetazolamide) at the 
respective time point. Z- scores are presented in parenthesis where appropriate.
α1- AGP, alpha-1 acid glycoprotein.
Table 3 Baseline sea- level characteristics
Placebo Losartan P value
ACE genotype and pair no.
Female pairs Male pairs
Age (years) 38.6±18.5 40.4±18.0 0.83 1 ID ID 4 II II
Body mass (kg) 74.1±11.5 66.7±13.3 0.71 2 ID ID 5 II II
Height (cm) 172.6±8.4 176.4±8.9 0.83 3 ID ID 6 ID ID
GFR (mL/min/1.73 m2) 88.0±15.2 90.8±15.8 0.69   7 ID ID
eGFR (mL/min/1.73 m2) 87.8±15.3 90.8±15.9 0.68   8 ID ID
Creatinine (μmol/L)* 84.5±24.0 81.0±31.0 0.58   9 DD ID
    10 DD DD
Baseline results were obtained at sea level and prior to the administration of placebo and losartan. Results for continuous variables 
are reported as mean±SD unless indicated by *, where values are reported as median ± IQR. ACE genotypes are presented as allelic 
variations (II, ID and DD). Significance was set to p value <0.05. No significant differences between groups were evident at baseline sea 
level. Subjects were equally matched for sex (men and women). All genotypes were observed and 90% matched.
eGFR, estimated glomerular filtration rate (calculated using the MDRD study equation); GFR, glomerular filtration rate; MDRD, 
Modification of Diet in Renal Disease.
groups with excretion rates peaking at post-60 min 
(figure 3A). Urinary α1- AGP excretion at post-60 min 
was similar between groups (p=0.63) and resolved after 
120 min in both groups (figure 3A).
Altitude (placebo vs losartan)
Altitude exercise results are presented in table 2 and 
figure 3B. Collectively, pre- exercise α1- AGP excretion 
was elevated at altitude compared with sea level, although 
excretion rates were similar between groups (p=0.62). 
The odds ratio (OR) for a relative increase in α1- AGP 
excretion at rest (pre-120, post-120, post-180 min) was 
2.16 times greater without losartan at altitude.
Altitude exercise significantly increased urinary 
α1- AGP excretion in both placebo (χ2(3)=10.73, p=0.013) 
and losartan (χ2(3)=15.86, p<0.01) groups (figure 3B). 
Post-60 min α1- AGP excretion was lower with losartan 
compared with placebo, although the difference was not 
statistically significant (p=0.28, figure 3B and table 2).
In the losartan group only, the change in α1- AGP excre-
tion from pre-60 min to post-60 min was lower compared 
School. Protected by copyright.
 o
n
 April 20, 2020 at Barnes Library M
edical
http://bmjopensem.bmj.com/
BM
J O
pen Sport Exerc M
ed: first published as 10.1136/bmjsem-2019-000662 on 26 March 2020. Downloaded from 
7Joyce KE, et al. BMJ Open Sp Ex Med 2020;6:e000662. doi:10.1136/bmjsem-2019-000662
Open access
Figure 2 Daily measures of blood pressure and 24- hour urinary α1- AGP excretion rates with ascent. (A) Daily SBPs (mm 
Hg). (B) Daily DBPs (mm Hg). Data are plotted as daily medians with error bars representing the respective IQRs. (C) Log- 
transformed 24- hour urinary α1- AGP excretion rates (μg/min) by days with ascent. Data are plotted as the mean log of 24 hours 
α1- AGP with error bars representing SD of the respective group mean on each day. Twenty- four- hour urinary α1- AGP excretion 
collectively increased with ascent (p<0.01) with no difference between groups (p=0.97). α1- AGP, alpha-1 acid glycoprotein; 
DBPs, diastolic blood pressures; SBPs, systolic blood pressures.
with those changes observed at baseline, although this 
difference was not significant (p=0.059, figure 3D). The 
OR for reduced urinary α1- AGP excretion at post-60 min 
(sea level vs first altitude test) was 2.25 times greater with 
losartan.
Altitude (placebo vs placebo +acetazolamide)
Results for comparisons of post- exercise α1- AGP between 
placebo and placebo +acetazolamide are presented in 
tables 1 and 2 and figure 3C,E. As with placebo, altitude 
exercise tests, placebo +acetazolamide exercise resulted 
in an increase in urinary α1- AGP excretion (χ2(3)=10.73, 
p=0.01, figure 3C). Despite similar exercise peak power 
outputs (table 1) between placebo and placebo +acetazol-
amide tests, post- exercise α1- AGP excretion (at 60 min 
post- exercise) was significantly lower following placebo 
+acetazolamide exercise (p=0.025, figure 3C). Exercise- 
induced increases in α1- AGP excretion (change from 
pre- exercise to post-60 min) were significantly reduced 
(p=0.036) with acetazolamide by nearly threefold 
(figure 3E). These changes were not correlated (r=−0.10, 
p=0.82) with the significant improvements in pre- exercise 
SpO
2
 or SpO
2
 at Watt
max
 with acetazolamide administration 
(table 2). No difference was observed between losartan and 
losartan +acetazolamide tests (data not shown).
DIsCussIon
Compared with sea level and despite substantial systemic 
hypoxia at Watt
max
, post- exercise α1- AGP excretion was 
not greater at altitude suggesting that hypoxia is not the 
primary mechanism. Altitude- related reductions in exer-
cise intensity could, in part, explain this result,30 but they 
would fail to explain the increased likelihood for post- 
exercise α1- AGP to be lower with losartan compared 
with placebo when exercise intensities were similar. We 
had expected that losartan would mitigate BP amplifi-
cations and thus lower post- exercise α1- AGP, however 
we observed no difference in the BP response to exer-
cise between groups. Therefore, we have no evidence to 
attribute post- exercise α1- AGP responses to alterations in 
31BP or peritubular pressures.32
The direct action of ARBs within the glomerular 
filtration barrier on ATIs of podocytes16 could provide 
an alternative explanation. Activation of AT1s on 
podocytes induces heparanase expression, which 
promotes the cleavage of heparan sulfate and inhibits 
the production and secretion of heparan sulfate 
proteoglycans (HSPGs).33 The net result is neutralisa-
tion of the negatively charged HSPGs which limits the 
charge- selective function of the glomerular basement 
membrane (GBM).34 Blocking AT1s with losartan thus 
promotes the localised retention of negatively charged 
proteins at the GBM35 and limits the charge- selectivity 
impairment36 which, in the present study, manifests as 
a reduction in the extent of post- exercise α1- AGP. This 
hypothesis is consistent with findings related to the 
intensity- dependent increases in angiotensin- II37 and 
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Figure 3 Pre- exercise and post- exercise urinary α1- AGP excretion (μg/min) rates. (A) Comparisons between placebo 
versus losartan groups at baseline sea level; (B) comparisons between placebo versus losartan groups at altitude (first 
altitude exercise); (C) comparisons between placebo versus placebo +acetazolamide at altitude (second altitude exercise); 
(D) comparisons between baseline versus altitude in both placebo and losartan groups (change in α1- AGP from pre-60 min 
to post-60 min, Δα1- AGP) and (E) comparisons between placebo versus placebo +acetazolamide. Results are plotted as the 
group median (or individual values, D) with error bars representing the relative IQRs of the group. Significance was set to p 
value ≤0.05 unless otherwise indicated. Representing significance: * for the significant effect of exercise on urinary α1- AGP 
excretion; ** for the significant difference between groups at post-60 min and *** for the significant difference between placebo 
and placebo +acetazolamide for Δα1- AGP (D) or for the trend (p=0.059) of difference between baseline and the first altitude for 
Δα1- AGP (E). α1- AGP, alpha-1 acid glycoprotein.
exercise- related increases in α1- AGP,38 although further 
investigations are required.
Reductions in post- exercise α1- AGP by acetazolamide 
were unrelated to the significant improvements in 
exercise SpO
2
 at similar intensity (these effects of acet-
azolamide on exercise performance were previously 
published and support previous findings).26 39 On its 
own, this would provide further support indicating that 
hypoxia is not the primary mechanism of post- exercise 
proteinuria. Unfortunately, the post- exercise effects of 
acetazolamide cannot be separated from the acclimati-
sation effect. Thus, no definitive conclusion regarding 
acetazolamide’s effects on post- exercise proteinuria can 
be provided. Future research is required to evaluate 
acetazolamide- related changes in post- exercise protein-
uria. Nonetheless, acetazolamide results support recent 
evidence demonstrating performance limiting effects of 
acetazolamide despite of its ability to elicit improvements 
in oxygen saturation.40
limitations and future directions
The inability to control for extraneous variables (eg, 
activity, sleep, environmental conditions) as well as low 
subject numbers were weaknesses of the present study 
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but they are common limitations for such field- based 
research. Not controlled for were the inter- individual 
variability7 and between- day variations in α1- AGP excre-
tion which could have impacted results. Future research 
could be strengthened by incorporating a sea- level 
control arm that compared post- exercise proteinuria 
between exercise tests executed 48 hours apart. Benefit 
could also be gained by using a less complex design and 
avoiding overlapping factors (eg, acclimatisation status 
and time course of exercise tests in this case). Lastly, 
further research is needed in order to confirm the rela-
tionship between DBP and 24 hours α1- AGP excretion.
ConClusIon
Our findings suggest that post- exercise α1- AGP is (1) 
more related to exercise intensity than degree of hypoxia 
or BP and (2) possibly influenced by activation or inhibi-
tion of AT1 receptors. Losartan may limit post- exercise 
proteinuria by helping to maintain the charge- selectivity 
function in the glomerular filter, although further inves-
tigations are required for evaluation.
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